azer-cel (azercabtagene zapreleucel)

About Imugene

Imugene is a clinical-stage biotech with a mission to develop transformative cancer medicines by leveraging a multi-platform strategy focused on immuno-oncology. Its key achievements include advancing a pipeline of seven candidates, most notably the off-the-shelf CAR-T therapy azer-cel and the oncolytic virus platform CF33, with several programs now in Phase 1/2 clinical testing. The company's strategy mitigates risk by pursuing diverse therapeutic modalities and targets, often in combination with standard of care, to address significant unmet needs in oncology. It operates with a capital-efficient model, supported by a world-class scientific advisory board and strategic collaborations.

Therapeutic Areas